Suppr超能文献

时间紧迫:肯尼亚从符合治疗条件之时起开始抗逆转录病毒治疗的速度和及时性。

The clock is ticking: the rate and timeliness of antiretroviral therapy initiation from the time of treatment eligibility in Kenya.

作者信息

Odeny Thomas A, DeCenso Brendan, Dansereau Emily, Gasasira Anne, Kisia Caroline, Njuguna Pamela, Haakenstad Annie, Gakidou Emmanuela, Duber Herbert C

机构信息

Institute for Health Metrics and Evaluation, University of Washington Seattle, WA, USA.

Kenya Medical Research Institute, Nairobi, Kenya;

出版信息

J Int AIDS Soc. 2015 Oct 26;18(1):20019. doi: 10.7448/IAS.18.1.20019. eCollection 2015.

Abstract

INTRODUCTION

Understanding the determinants of timely antiretroviral therapy (ART) initiation is useful for HIV programmes intent on developing models of care that reduce delays in treatment initiation while maintaining a high quality of care. We analysed patient- and facility-level determinants of time to ART initiation among patients who initiated ART in Kenya.

METHODS

We collected facility-level information and conducted a retrospective chart review of adults initiating ART between 2007 and 2012 at 51 health facilities in Kenya. We evaluated the association between patient- and facility-level covariates at the time of ART eligibility and time to ART initiation. We also explored the determinants associated with timeliness of ART initiation.

RESULTS

The analysis included 11,942 patients. The median age at the time eligibility was first determined was 37 years (interquartile range [IQR] 31-45). Overall, 75% of patients initiated ART within two months of eligibility. The median CD4 cell count at the time eligibility was first determined rose from 132 (IQR 51-217) in 2007 to 195 (IQR 91-286) in 2011 to 2012 (p<0.001). The cumulative probability of ART initiation among treatment-eligible patients increased over time: 87.1% (95% confidence interval [CI] 85.1-89.0%) in 2007; 96.8% (96.0-97.5%) in 2008; 97.1% (96.3-97.7%) in 2009; 98.5% (98.0 -98.9%) in 2010; and 99.7% (95% CI 99.4 -99.8%) in 2011 to 2012 (p<0.0001). In multivariate analyses, attending a health facility with high ART patient volumes within two months of eligibility was considered the key facility-level determinant of ART initiation (adjusted odds ratio 0.57, 95% CI 0.45-0.72, p<0.001). Patient-level determinants included being eligible for ART in the years subsequent to 2007, advanced World Health Organization clinical stage and low CD4 cell count at the time eligibility was first determined.

CONCLUSIONS

Overall, the time between treatment eligibility and ART initiation decreased substantially in Kenya between 2007 and 2012, with uniform gains across different types of health facilities. Our findings highlight the slow increase in CD4 cell counts at the time of ART eligibility over time, indicating that a large number of patients are still beginning ART with advanced HIV disease. Our findings also support the decentralisation of ART services at all health facilities that have the capacity to initiate treatment. Continued evaluation of programme- and country-level data is needed to monitor timeliness of ART initiation as countries continue to expand treatment access.

摘要

引言

了解及时启动抗逆转录病毒疗法(ART)的决定因素,对于旨在建立护理模式以减少治疗启动延迟同时保持高质量护理的艾滋病毒项目很有用。我们分析了肯尼亚开始接受抗逆转录病毒治疗的患者中,与启动治疗时间相关的患者层面和机构层面的决定因素。

方法

我们收集了机构层面的信息,并对2007年至2012年期间在肯尼亚51家医疗机构开始接受抗逆转录病毒治疗的成年人进行了回顾性病历审查。我们评估了在符合抗逆转录病毒治疗条件时患者层面和机构层面协变量与开始接受抗逆转录病毒治疗时间之间的关联。我们还探讨了与及时启动抗逆转录病毒治疗相关的决定因素。

结果

分析纳入了11,942名患者。首次确定符合条件时的中位年龄为37岁(四分位间距[IQR] 31 - 45)。总体而言,75%的患者在符合条件后的两个月内开始接受抗逆转录病毒治疗。首次确定符合条件时的中位CD4细胞计数从2007年的132(IQR 51 - 217)升至2011年至2012年的195(IQR 91 - 286)(p<0.001)。符合治疗条件的患者开始接受抗逆转录病毒治疗的累积概率随时间增加:2007年为87.1%(95%置信区间[CI] 85.1 - 89.0%);2008年为96.8%(96.0 - 97.5%);2009年为97.1%(96.3 - 97.7%);2010年为98.5%(98.0 - 98.9%);2011年至2012年为99.7%(95% CI 99.4 - 99.8%)(p<0.0001)。在多变量分析中,在符合条件后的两个月内就诊于抗逆转录病毒治疗患者量大的医疗机构被认为是启动抗逆转录病毒治疗的关键机构层面决定因素(调整后的优势比为0.57,95% CI 0.45 - 0.72,p<0.001)。患者层面的决定因素包括在2007年之后符合抗逆转录病毒治疗条件、世界卫生组织临床分期较晚以及首次确定符合条件时CD4细胞计数较低。

结论

总体而言,2007年至2012年期间,肯尼亚从符合治疗条件到开始接受抗逆转录病毒治疗的时间大幅缩短,不同类型的医疗机构均有一致改善。我们的研究结果突出显示,随着时间推移,符合抗逆转录病毒治疗条件时CD4细胞计数增长缓慢,这表明大量患者仍在艾滋病晚期才开始接受抗逆转录病毒治疗。我们的研究结果还支持在所有有能力启动治疗的医疗机构中下放抗逆转录病毒治疗服务。随着各国继续扩大治疗可及性,需要持续评估项目和国家层面的数据,以监测抗逆转录病毒治疗启动的及时性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/acfb/4623278/3f28e802c2a3/JIAS-18-20019-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验